oliceridine · Trevena · NDA 210730
Olinvyk
Earliest generic entry, as listed · earliest of 3 marketed strengths
23 Mar 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11077098, US 11931350, US 8835488, US 9309234, US 9642842.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11077098 | drug substance, drug product, use U-2986 · sets the listed date | 23 Mar 2032 |
| US 11931350 | drug substance, use U-2986 · sets the listed date | 23 Mar 2032 |
| US 8835488 | drug substance, drug product, use U-2986 · sets the listed date | 23 Mar 2032 |
| US 9309234 | drug substance, drug product, use U-2986 · sets the listed date | 23 Mar 2032 |
| US 9642842 | drug product, use U-2986 · sets the listed date | 23 Mar 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210730 · 001 · RLD · discontinued | solution, intravenous | 1MG/ML (1MG/ML) | 23 Mar 2032 |
| 210730 · 002 · RLD · discontinued | solution, intravenous | 2MG/2ML (1MG/ML) | 23 Mar 2032 |
| 210730 · 003 · RLD · discontinued | solution, intravenous | 30MG/30ML (1MG/ML) | 23 Mar 2032 |